Joe. everyone. you, afternoon, Thank Good
and platform. the third internal During across portfolio by our we full-scale collaborative advances of make quarter, of powered to our continued deployment pipeline programs
this clinic on track have to clinical year. our programs is Several next first collaborative advanced programs in The development year. of the begin internal
's studies, announcement to the year. in MORF-XXX recent are QX about excited about We X initiate next Phase Morphic preparations
Our programs will target multi-target data the largest the our regarding this with collaboration partnership, Myers GXXX that is another today progressing. FDA that and drug that HIF-Xalpha [Indiscernible] on e-mutant the precision discovery to We have we there are are focusing Bristol now rights announced program, full program. approved but another our now prioritized are and prevalence with companies how resources We HIF-Xalpha replace promising is we pending, an are target. given oncology Squibb inhibitor have the still pleased
that agreement for of as as to bi-functional through blocking eliminate than proteasomal the we same degraders, a all degraders pathway. Rather and today a announced existing our modality, the have expanded develop, promising a new We our bi-functional together also in collaboration. targets BMS the which emerged partnership commercialize with target discover, proteins can degradation have activity
have Turning annual internal programs we we resident clinical of will include, meeting. development. week, team, we of program of - in of to research support data we with at into strong compounds clinical discovery MALTX from best-in-class a data MALTX internal data and -clinical our as showing lymphoma. the opportunity of our activity, Last the strong potent our in pleased reported move Subject we expert the potential lead we we inhibition to team very characteristics binding and proliferative effects new anti Overall, pipeline, This are addition are an believe completion to advancement of for that a affinity, MALTX to MALTX models translational preclinical the clinic. -clinical ASH prepare building inhibitor to the enzymatic pre our will pre our multiple present package. and inhibitors with
the our year. next development the for the MALTX half IND candidate We FDA track to of on in are to first submit
are making progress great program. our also with CDCX We
a making momentum to therapeutic We proliferative damage, that have this is to bypass year. in gaining replication to this CDCX responses targeting stress second damage cancer. and built potent development enabling candidate, knight normal studies capacity, selected DNA proteins a be plan enter for ability of approach IND replication, cells, and is cancer roles DNA to program the
of provide malignancies for in marketed further CDCX peak date and clinic, hematological inhibitors in in other strong potentially in combination the AML both with compelling and have believe studies anti-tumor tumors. models Our data we preclinical We [Indiscernible] in generated activity the solid agents. opportunities to have
cells tyrosine is regulator and as by cells shown WEEX, target. GXM program, have in activity a of been has to discovery kinase cycle tumors. in when reduces solid late-stage liability damage third a checkpoint, inducing DNA which apoptosis WEEX cell repair Our also is inhibited, studies third-party cancer clinical
position candidates announced accelerate multiple drug-like activity. or of validation profile and pharmacodynamic identified as responses highly University collaboration that our We applications, this research and In biomarkers The pre this for in Anderson clinical combination predict have program collaboration agents. biomarker strategic both and development -clinical may MD to October, patient We our believe a of with the type [Indiscernible] inhibitors selective optimize desirable monotherapy Cancer driven the shows anti-tumor compounds through models. of promising weX path with Center. for properties with we Texas inhibitor. response goal prioritization, strong other is weX assistance to tumor In and stratification, as that
biological are new pipeline. to As look established of programs wards our first have select adding validation. targets or clinical X the clinic, internal our to advance we're new When we programs, programs we enabled that and for structurally
submissions to and an applying believe and program. enable announced we advantage, and our underway program In several platform. have we're to wholly-owned addition solve internal the programs capabilities pipeline. challenge oncology design prediction us more clinical of by give within a Additionally, to expect to our our structure an year. XXXX. collaborative portfolio where we R&D continues August In refinement computational are advance next undisclosed and immunology now can pipeline X summary, we protein start an today, look programs We undisclosed our our trials activities in diverse targets where for initiate announcing the and And precision of we
multiple progress pleased and to extremely with the we call ahead I'll are back turn us. have value-creating now opportunities overall Ramy. of believe We the
